BR112015024472A2 - multifunctional quinoline derivatives as anti-neurodegenerative agents - Google Patents

multifunctional quinoline derivatives as anti-neurodegenerative agents

Info

Publication number
BR112015024472A2
BR112015024472A2 BR112015024472A BR112015024472A BR112015024472A2 BR 112015024472 A2 BR112015024472 A2 BR 112015024472A2 BR 112015024472 A BR112015024472 A BR 112015024472A BR 112015024472 A BR112015024472 A BR 112015024472A BR 112015024472 A2 BR112015024472 A2 BR 112015024472A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
neurodegenerative
multifunctional
compound
composition
Prior art date
Application number
BR112015024472A
Other languages
Portuguese (pt)
Inventor
Huang Chen-Wei
Chern Ji-Wang
Teh Chang Pei
Subhash Talekar Rahul
Original Assignee
Annji Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharm Co Ltd filed Critical Annji Pharm Co Ltd
Publication of BR112015024472A2 publication Critical patent/BR112015024472A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

resumo derivados de quinolina multifuncionais como agentes anti-neurodegenerativos derivados de quinolina novos são divulgados. também divulgados são a sua síntese e uso para tratamento de doenças neurodegenerativas. em um aspecto, a invenção se refere a uma composição compreendendo uma quantidade terapeuticamente eficaz do composto conforme mencionado acima, ou um sal farmaceuticamente aceitável, um solvente ou hidrato, uma pró-droga ou um metabolito respectivo, e um diluente farmaceuticamente aceitável ou carreador. em um aspecto adicional, a invenção se refere a uma composição compreendendo um composto conforme mencionado acima, ou um sal farmaceuticamente aceitável, um solvente ou hidrato, uma pró-droga ou um metabolito respectivo, e um diluente farmaceuticamente aceitável ou carreador para uso no tratamento de uma doença neurodegenerativa. em ainda outro aspecto, a invenção se refere a uma composição compreendendo um composto conforme mencionado acima na fabricação de um medicamento para o tratamento de uma doença neurodegenerativa. em uma modalidade, o medicamento é para o tratamento da doença de alzheimer. 1/1 registro legal no: 14507-55141Summary Multifunctional quinoline derivatives as novel quinoline derivative anti-neurodegenerative agents are disclosed. Also disclosed are their synthesis and use for treating neurodegenerative diseases. In one aspect, the invention relates to a composition comprising a therapeutically effective amount of the compound as mentioned above, or a pharmaceutically acceptable salt, a solvent or hydrate, a prodrug or a metabolite thereof, and a pharmaceutically acceptable diluent or carrier. In a further aspect, the invention relates to a composition comprising a compound as mentioned above, or a pharmaceutically acceptable salt, a solvent or hydrate, a prodrug or a metabolite thereof, and a pharmaceutically acceptable diluent or carrier for use in the treatment. of a neurodegenerative disease. In yet another aspect, the invention relates to a composition comprising a compound as mentioned above in the manufacture of a medicament for treating a neurodegenerative disease. In one embodiment, the drug is for the treatment of Alzheimer's disease. 1/1 legal registration no: 14507-55141

BR112015024472A 2013-04-02 2013-04-02 multifunctional quinoline derivatives as anti-neurodegenerative agents BR112015024472A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/034960 WO2014163622A1 (en) 2013-04-02 2013-04-02 Multifunctional quinoline derivatives as anti-neurodegenerative agents

Publications (1)

Publication Number Publication Date
BR112015024472A2 true BR112015024472A2 (en) 2017-07-18

Family

ID=51658752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015024472A BR112015024472A2 (en) 2013-04-02 2013-04-02 multifunctional quinoline derivatives as anti-neurodegenerative agents

Country Status (9)

Country Link
EP (1) EP2981525A4 (en)
JP (1) JP6153179B2 (en)
KR (1) KR101802048B1 (en)
CN (1) CN105452224B (en)
AU (1) AU2013385618B2 (en)
BR (1) BR112015024472A2 (en)
IL (1) IL241295A0 (en)
RU (1) RU2642466C2 (en)
WO (1) WO2014163622A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101725326B1 (en) * 2015-04-23 2017-04-12 대한민국 A novel isolated midroorganism having antibiotic activity and a production method of pseudane using the same
CN105949120B (en) * 2016-05-27 2018-07-24 广东工业大学 A kind of application of four teeth chelating type list quinoline and preparation method thereof and metal ion control agent as neurodegenerative disease
KR102281647B1 (en) * 2020-12-09 2021-07-30 메디케어제약 주식회사 Method of producing a derivative-piperazine
CN113527200B (en) * 2021-05-27 2022-12-02 北京斯利安药业有限公司 Preparation method of cloquinadol

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682927A (en) * 1968-06-15 1972-08-08 Massimo Carissimi 5,7-bichloro-8-hydroxy-2-acetylamino quinoline
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
DK0666855T3 (en) * 1992-10-27 1996-10-07 Janssen Pharmaceutica Nv 4-quinolinyl derivatives with anti-Helicobacter activity
IL128416A (en) * 1996-08-13 2004-06-01 Gerolymatos P N Sa Use of clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease and pharmaceutical composition comprising same
ATE280759T1 (en) * 1997-07-07 2004-11-15 Kowa Co DIAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2819507B1 (en) * 2001-01-17 2007-09-28 Inst Rech Developpement Ird SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS
KR101020399B1 (en) 2002-03-27 2011-03-08 글락소 그룹 리미티드 Quinolin Derivatives and Their Use as 5-HT6 Ligands
CA2484959A1 (en) 2002-04-30 2003-11-13 Yungjin Pharmaceutical Co., Ltd. Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
JP4790594B2 (en) * 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Hydroxamic acid compounds containing bicyclic heteroaryl groups as HDAC inhibitors
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
WO2005035534A1 (en) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
FR2889525A1 (en) * 2005-08-04 2007-02-09 Palumed Sa NOVEL POLYQUINOLINE DERIVATIVES AND THEIR THERAPEUTIC USE.
JP2009544631A (en) * 2006-07-25 2009-12-17 エンビボ ファーマシューティカルズ インコーポレイテッド Quinoline derivatives
CN102239149B (en) * 2008-10-06 2015-05-13 约翰·霍普金斯大学 Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
AU2011258217B2 (en) * 2010-05-26 2016-12-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN102526052B (en) * 2012-01-19 2013-10-09 华南师范大学 Application of 2-gylcosyl chinoline compound in preparing acetylcholine esterase resisting medicines

Also Published As

Publication number Publication date
CN105452224A (en) 2016-03-30
JP2016515617A (en) 2016-05-30
EP2981525A4 (en) 2016-12-21
WO2014163622A8 (en) 2014-11-13
CN105452224B (en) 2017-12-26
KR20150136070A (en) 2015-12-04
KR101802048B1 (en) 2017-12-28
EP2981525A1 (en) 2016-02-10
IL241295A0 (en) 2015-11-30
RU2015137621A (en) 2017-05-11
WO2014163622A1 (en) 2014-10-09
AU2013385618B2 (en) 2017-01-05
AU2013385618A1 (en) 2015-09-24
JP6153179B2 (en) 2017-06-28
RU2642466C2 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
CY1119490T1 (en) PYRAZOLOPYROLIDINE PRODUCTS AND THEIR USE IN PATIENT TREATMENT
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
CY1122566T1 (en) 6,7,8,9-TETPAYDP-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
EA201490774A1 (en) NEW OXAZINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF THE DISEASE
EA201490888A1 (en) NEW PURIN DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
UA109698C2 (en) AZAINDASOL OR DIAZAINDASOL DERIVATIVES AS A MEDICINE
EA201391029A1 (en) OXAZIN DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF NEUROLOGICAL DISORDERS
BR112015016315A2 (en) fluoro- [1,3] oxazine as bace1 inhibitors
BR112016003229A8 (en) compound, pharmaceutical composition, and, use of a compound or pharmaceutical composition
EA201592255A1 (en) DERIVATIVES OF PYRAZOLOPIRROLIDIN-4-IT AS A BET INHIBITOR AND THEIR APPLICATION IN THE TREATMENT OF THE DISEASE
EA201691151A1 (en) CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS
CY1124243T1 (en) INHIBITING THE A1 TRANSIENT POTENTIAL RECEPTOR ION CHANNEL
EA201591291A1 (en) DERIVATIVES OF PYRIMIDON AND THEIR APPLICATION IN TREATMENT, FACILITATION OR PREVENTION OF VIRAL DISEASE
EA201592254A1 (en) DERIVATIVES OF Pyrazolopyrrolidin-4-IT and THEIR APPLICATION IN THE TREATMENT OF DISEASE
EA202090860A1 (en) THIADIAZOL ANALOGUES AND METHODS FOR TREATMENT OF CONDITIONS RELATED TO SMN DEFICIENCY
EA201391106A1 (en) NEW HETEROCYCLIC DERIVATIVES
EA201690247A1 (en) AMINOMETHYBYRIL DERIVATIVES-INHIBITORS OF COMPLEX D FACTOR AND USE
EA201391485A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EA201391486A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
BR112015019412A2 (en) bace1 inhibitors
BR112014001908A2 (en) substituted heterocyclic aza derivatives
UA117154C2 (en) S1p3 antagonists
EA201692298A1 (en) DERIVATIVES OF CARBOXAMIDES
UY32829A (en) DERIVATIVES OF 3-HETEROARIL-METIL-IMIDAZO- [1,2-B] -PIRIDIDAZIN - 6 -ILO
BR112015024472A2 (en) multifunctional quinoline derivatives as anti-neurodegenerative agents

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2508 DE 29-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.